+612 9045 4394
 
CHECKOUT
Anabolic Therapy in Modern Medicine - William N. Taylor

Anabolic Therapy in Modern Medicine

Paperback

Published: 1st February 2002
Ships: 15 business days
15 business days
RRP $197.99
$143.75
27%
OFF
or 4 easy payments of $35.94 with Learn more

Anabolic therapies have been found to be useful in the treatment of numerous diseases and conditions and their medical uses continue to expand. This work is a technical and comprehensive study of anabolic therapy, covering a wide range of diseases and conditions. Beginning with a description of anabolic agents and their historical medicinal use, the author provides a rationale for the use of anabolics in treating sarcopenia, CST-induced and postmenopausal osteoporosis, hormone replacement therapy in women, osteoporosis and andropause in men; the autoimmune diseases ALS, Chronic Fatigue Syndrome, MS, rheumatoid arthritis, Sjogren's Syndrome, systemic lupus erythematosus, and systemic sclerosis; stroke treatment and rehabilitation, Type II diabetes in men, and AIDS. Also provided is rationale for the use of anabolic therapies in addition to cancer therapy in cardiopulmonary rehabilitation, spinal cord injuries and other conditions with secondary hypogonadism, dementia, Alzheimer's, depression, and other CNS conditions, musculoskeletal conditions, major burns, wound healing, and the use of anabolic therapies in addition to TPN and nutrition in microgravity, prolonged immobilization, and space travel conditions, chronic anemias, and related conditions.

Prefacep. 1
Androgens: Synthesis and Scope of Chemical Potentials
Introduction: Anabolic Therapy and the Body's Catabolic Responses to Ill-Health Conditionsp. 5
Historical Use of Anabolic Agents in Medicinep. 9
Introduction: Defining the Breadth of Anabolic Agentsp. 9
Defining the Scope of Patients Who Require Anabolic Therapiesp. 10
Summary: Anabolic Therapy Is the Future of Medicinep. 11
Anabolic Therapy for Sarcopenia, Osteoporosis, and Hormone Replacement Therapy
Rationale for Anabolic Therapy in Sarcopenia and Frailty Conditionsp. 15
Introduction: Sarcopenia: The Condition of the 21st Centuryp. 15
The Need to Reeducate Health Care Providersp. 16
Hypoandrogenemia and Hyposomatomedinemia in Sarcopeniap. 17
Androgen and Other Anabolic Therapies for Sarcopeniap. 18
Androgen Therapy for Sarcopenic States Associated with Chronic Illnessesp. 22
Additional Health Benefits of Androgen Therapy in Sarcopenic Statesp. 22
Rationale for Anabolic Therapy in Corticosteroid-Induced Osteoporosisp. 32
Introduction: Iatrogenic Bone Diseasep. 32
Hypoandrogenemia and Hyposomatomedinemia in CST-Induced Osteoporosisp. 33
Reduced Bone Formationp. 34
Increased Bone Resorptionp. 38
Altered Calcium Metabolismp. 38
Altered Bone Architecturep. 39
Studies with Anabolic Therapy for CST-Induced Osteoporosisp. 39
Rationale for Anabolic Therapy for Postmenopausal Osteoporosis and Hormone Replacement Therapy in Womenp. 51
Introduction: Postmenopausal Androgen Deficiency and Underutilization of Androgen Therapyp. 51
Androgen Deficiency Links Many Diseases in Postmenopausal Womenp. 53
Barriers for Adequate Management of Postmenopausal Osteoporosisp. 55
Androgen Therapy Mimics Ovarian Functionp. 56
Androgen Therapy Reverses BMD Deficits in Postmenopausal Osteoporosisp. 57
Historical Highlights Regarding the Clinical Use of Androgen Therapy in Womenp. 58
Androgens Directly and Indirectly Stimulate Normal Bone Formationp. 62
Androgen Therapy Corrects Hypoandrogenemia and Hyposomatomedinemiap. 63
Androgen Therapy Improves Menopausal Vasomotor Symptoms, Elevates Mood, Increases Libido, Improves Quality of Life, and Modulates Anabolic Cytokinesp. 64
Impact of Estrogen-Androgen HRT on Lipids and Thromboemobolic Event Risksp. 67
Rationale for Anabolic Therapy for Osteoporosis and Andropause in Menp. 88
Introduction: Andropause Contributes to Osteoporosis and Other Diseases in Menp. 88
Redefining Andropause in Menp. 90
Historical Highlights of Androgen Therapy for Andropause in Menp. 90
Androgens Directly and Indirectly Stimulate Normal Bone Formationp. 92
Androgen Therapy Corrects Hypoandrogenemia and Hyposomatomedinemiap. 93
Hypoandrogenemia, Androgen Therapy, and Risk for Prostate Cancer and Benign Prostatic Hypertrophyp. 94
Hypoandrogenemia, Androgen Therapy, and Cardiovascular Risk Factorsp. 97
Androgen Therapy and Its Neurosteroid, Neuroprotective, and Neuroimmune Benefitsp. 99
Anabolic Therapy for Autoimmune Diseases
Rationale for Anabolic Therapy in Autoimmune Diseasesp. 119
Introduction: Abnormal Sex Steroid Profiles?p. 119
Gender Dimorphism in Autoimmune Diseasesp. 120
Androgens Are Immunomodulating Agentsp. 122
Androgens Are Neuroprotective and Neuroregenerative Agentsp. 125
Androgens Are Potent Neurosteroidsp. 127
Androgens Are Anabolic Agentsp. 129
Androgens Are Osteoblast Stimulatorsp. 130
Rationale for Anabolic Therapy in Amyotrophic Lateral Sclerosisp. 145
Introduction: Anabolic and Neurotrophin Factor Deficiency?p. 145
Anabolic Therapy for ALSp. 147
Rationale for Anabolic Therapy in Chronic Fatigue Syndromep. 150
Introduction: Chronic Fatigue Syndrome: A Neurosteroid Deficiency?p. 150
Hypoandrogenemia and CFSp. 150
Studies with Anabolic Therapy in CFSp. 151
Rationale for Anabolic Therapy in Multiple Sclerosisp. 155
Introduction: A Major Loss of Anabolic Potentials to Counteract Severe Catabolismp. 155
Hypoandrogenemia and Hyposomatomedinemia in MSp. 156
Anabolic Therapy for MS Patients in Rehabilitationp. 157
Rationale for Anabolic Therapy in Rheumatoid Arthritisp. 164
Introduction: Androgens, the Missing Hormones in RAp. 164
Mechanisms of Hypoandrogenemia in RAp. 165
Androgen Therapy in RA and for RA-Related Sequelaep. 167
Rationale for Anabolic Therapy in Sjogren's Syndromep. 175
Introduction: Hypoandrogenemia Associated with Sjogren's Syndromep. 175
Pathologic Mechanisms and Hypoandrogenemia in SSp. 176
Studies with Androgen Therapy in SSp. 177
Rationale for Anabolic Therapy in Systemic Lupus Erythematosusp. 183
Introduction: Sex Hormones and SLEp. 183
Androgen Deficiency and SLEp. 184
Studies with Androgen Therapy in SLEp. 185
Androgen Therapy and Cytokine Profiles in SLEp. 186
Rationale for Anabolic Therapy in Systemic Sclerosisp. 193
Introduction: Scleroderma and Androgen Deficiencyp. 193
Studies with Androgen Therapy for SScp. 194
Anabolic Therapy for Other Catabolic Diseases and Conditions
Rationale for Anabolic Therapy in AIDS and HIV Infectionp. 201
Introduction: Hypoandrogenemia and AIDS Wastingp. 201
Studies of Anabolic Therapy for HIV-Infected Patientsp. 202
Rationale for Anabolic Therapy in Burns and Major Thermal Injuriesp. 208
Introduction: A Prolonged Major Catabolic Conditionp. 208
Hypoandrogenemia and Hyposomatomedinemia in Major Burnsp. 208
Complications and Sequelae of Thermal Injury-Induced Hypoandrogenemia and Hyposomatomedinemiap. 209
Studies of Anabolic Therapy for Major Thermal Injuriesp. 209
Rationale for Anabolic Therapy in Cancer Patientsp. 217
Introduction: The Anorexia/Cachexia Syndrome: Description and Pharmacologic Managementp. 217
Hypoandrogenemia and Hyposomatomedinemia in Cancer Patientsp. 218
Studies with Androgen Therapy for Cancer Patientsp. 219
Rationale for Anabolic Therapy in Cardiovascular Diseases and Cardiac Rehabilitationp. 224
Introduction: Hypoandrogenemia Is a Multifacted Risk Factor for Heart Diseasep. 224
Hypoandrogenemia Promotes Cardiovascular Diseasep. 225
Incidence of Hypoandrogenemia and CHD in Menp. 226
Hypoandrogenemia Contributes to Hyposomatomedinemia and Heart Diseasep. 227
Androgens Are Beneficial Cardiovascular Agentsp. 228
Rationale for Anabolic Therapy in Chronic Obstructive Pulmonary Diseasep. 235
Introduction: A Major Catabolic Conditionp. 235
Hypoandrogenemia in COPD Patientsp. 235
Studies with Anabolic Therapy in COPDp. 236
Rationale for Anabolic Therapy in Stroke Treatment and Rehabilitationp. 241
Introduction: A Lack of Clinical Use of Anabolic Agents for Stroke Patientsp. 241
Androgen Deficiency and Low Anabolic Stimuli in Stroke Patientsp. 243
Androgen Deficiency, Atherogenesis, Fibrinolysis, and Thromboembolic Eventsp. 244
Androgens Are Neuroprotective Neurosteroids and Neuroendocrine Modulators of the Cytokine Systemp. 245
Conclusion: Androgens Play a Key Role in the Entire Constellation of Stroke Pathogenesis, Recovery, and Rehabilitationp. 246
Recommendations for Anabolic Therapyp. 250
Rationale for Anabolic Therapy in Type II Diabetes in Men: Medical Management and Rehabilitationp. 261
Introduction: Gender Dimorphism in Type II Diabetesp. 261
Hypoandrogenemia in Men with Type II Diabetesp. 263
Hypoandrogenemia Induces Hyposomatomedinemia in Men with Type II Diabetesp. 265
Consequences of Hypoandrogenemia and Hyposomatomedinemia in Men with Type II Diabetesp. 266
Available Studies of Androgen Therapy for Type II Diabetes in Menp. 267
Recommendations for Anabolic Therapy in Men with Type II Diabetesp. 267
Rationale for Anabolic Therapy in Chronic Renal Failurep. 274
Introduction: Uremic Hypoandrogenemia and Its Dramatic Clinical and Financial Impactsp. 274
Hypoandrogenemia in Patients with CRFp. 275
Hypoandrogenemia-Related Diseases and Conditions in Patients with CRFp. 276
Studies with Anabolic Therapy in CRFp. 277
Rationale for Anabolic Therapy in Muscular Dystrophy and Other Primary Myopathiesp. 283
Introduction: Many Myopathies Are Associated with Hypoandrogenemiap. 283
Anabolic Therapy for Myopathiesp. 284
Rationale for Anabolic Therapy in Spinal Cord Injuryp. 289
Introduction: Spinal Cord Injury Creates Catabolic Endocrine Abnormalitiesp. 289
Studies with Anabolic Therapy in SCIp. 290
Rationale for Anabolic Therapy in Alzheimer's Disease and Cognition Deficitsp. 294
Introduction: Reduced Anabolic Potentials Affect Cognitionp. 294
Studies with Anabolic Agents in Cognitive Dysfunction and ADp. 295
Rationale for Anabolic Therapy in Osteoarthritisp. 300
Introduction: Reduced Anabolic Processes Result in Joint Destructionp. 300
Systemic and Local Anabolic Losses in Osteoarthritisp. 300
Studies with Anabolic Therapy in Osteoarthritisp. 301
Rationale for Anabolic Therapy in Prolonged Immobilization, Microgravity, and Extended Space Travelp. 305
Introduction: Dramatic Losses of Anabolic Potentialsp. 305
Studies with Anabolic Therapy for Immobilization and Microgravity Conditionsp. 306
Rationale for Anabolic Therapy with Nutritional Replacement Treatmentsp. 309
Introduction: Critical Illness Is Associated with Profound Catabolism and Reduced Recuperative Abilitiesp. 309
Studies with Anabolic Agents and Nutritional Supportp. 310
Anabolic Therapy with GHRH-GH-IGF-IGFBP Axis Componentsp. 311
Rationale for Anabolic Therapy in Dermatological Maladies and Wound Healingp. 316
Introduction: Loss of Anabolic Potentials Delays Wound Healingp. 316
Anabolic Therapy and Mechanisms of Action for Wound Healingp. 317
Rationale for Anabolic Therapy in Miscellaneous Ill-Health Conditionsp. 320
Introduction: Loss of Anabolic Potential Can Result in a Variety of Ill-Health Conditionsp. 320
Fibromyalgiap. 320
Skeletal Muscle Contusions and Injuriesp. 321
Major Joint Replacement: Preoperational and Rehabilitationp. 321
Traumatic Brain Injuryp. 322
Afterword: Hypoandrogenemia Is the Most Commonly Missed Disorder in Modern Medicinep. 327
Indexp. 329
About the Authorp. 337
Table of Contents provided by Syndetics. All Rights Reserved.

ISBN: 9780786412419
ISBN-10: 0786412410
Audience: Professional
Format: Paperback
Language: English
Number Of Pages: 351
Published: 1st February 2002
Publisher: McFarland & Co Inc
Country of Publication: US
Dimensions (cm): 22.2 x 15.2  x 2.54
Weight (kg): 0.46
Edition Number: 2